

Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030

Market Report | 2025-06-10 | 325 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global exosome research market is projected to reach USD 480.6 million by 2030 from USD 214.4 million in 2025, at a CAGR of 17.5% during the forecast period. The expansion of the exosome research market is primarily fueled by the escalating incidence of chronic diseases, including cancer, neurodegenerative disorders, and CVDs; this trend underscores the urgent need for novel diagnostic and therapeutic strategies. Exosomes, due to their properties as potential biomarkers and their capacity to facilitate targeted therapeutic delivery, are uniquely positioned to address the increasing demand for advanced disease diagnostics and treatment modalities.

"The kits & reagents segment is expected to grow at the highest CAGR during the study period."

As academic institutions, biotechnology companies, and diagnostic developers delve deeper into the multifaceted roles of exosomes in disease diagnostics and therapeutic interventions, there has been a notable increase in the demand for standardized, user-friendly kits & reagents. These specialized tools play a crucial role in simplifying and expediting the workflows associated with exosome isolation, purification, labeling, and downstream analysis. Exosomes, nano-sized vesicles secreted by cells, have emerged as significant biomarkers in various diseases, necessitating precise handling and analysis. The standardization offered by commercially available kits helps ensure that researchers can perform these tasks with consistency and reliability, which is vital in both translational research and preclinical development. In particular, reproducibility is critical in scientific research; utilizing validated kits ensures consistent protocols that minimize variability and enhance overall research outcomes. This reliability is particularly pertinent in biomarker discovery and liquid biopsy research, where the identification of accurate biomarkers is paramount for early disease detection and monitoring. With the growing interest in exosome-based

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

diagnostics-especially within oncology for cancer detection and neurodegenerative diseases like Alzheimer's and Parkinson's-laboratories are increasingly opting for ready-to-use reagent systems. These systems facilitate sample preparation, RNA and DNA extraction, and comprehensive cargo profiling, thereby supporting a range of downstream molecular applications. The integration of such standardized tools not only streamlines the research process but also enhances the quality of data generated, ultimately contributing to the advancement of exosome research in clinical settings. As the landscape of diagnostics continues to evolve, the role of such reliable and efficient kits will become even more pronounced, paving the way for breakthroughs in personalized medicine and targeted therapies.

"North America is expected to grow at the highest CAGR in the global exosome research market from 2025 to 2030."

North America maintains its leading position in the global exosome research market, primarily due to substantial government investment and support mechanisms. Key organizations such as the National Institutes of Health (NIH) in the United States are pivotal, channeling significant funding into biomedical research, specifically targeting projects centered on exosomes. This financial endorsement empowers researchers to explore novel applications of exosomes in both diagnostics and therapeutics. For example, in June 2024, the National Heart, Lung, and Blood Institute (NHLBI) renewed a USD 12 million Program Project Grant (PPG) to support researchers at the Lewis Katz School of Medicine at Temple University. Their investigation focuses on heart cell-derived exosomes and their involvement in cardiac injury and repair processes. This funding facilitates a deeper understanding of the mechanisms by which exosomes contribute to myocardial tissue regeneration, potentially leading to groundbreaking therapeutic strategies. Likewise, in August 2023, the National Cancer Institute (NCI) allocated USD 2.5 million to the Sylvester Comprehensive Cancer Center to advance research on exosome-based biomarkers for prostate cancer detection through urine and blood assays. Such robust government backing not only propels scientific exploration but also fosters collaboration between academic institutions and industry, thereby cultivating a dynamic research ecosystem. This well-capitalized environment accelerates innovation and reinforces North America's status as a frontrunner in exosome research. As a result, the region continues to draw in investments and talent, driving ongoing growth within the exosome research sector.

In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side-70% and Demand Side-30%

-□By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%

-□By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%

List of Key Companies Profiled in the Report:

Key players in the exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), Danaher Corporation (US), Capricor Therapeutics(US), Lonza (Switzerland), QIAGEN (Germany), Creative Medical Technologies Holdings, Inc. (US), System Biosciences, LLC (US), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), Aethlon Medical, Inc. (US), Anjarium Biosciences AG (UK), Ciloa (France), InnovaPrep LLC (US), ILIAS Biologics, Inc. (South Korea), Unchained Labs (US), Rion, Inc. (US), Cell Guidance System, LLC (UK), INOVIQ (Australia), Exopharm (Australia), Everzom (France), RoosterBio, Inc. (US), Creative Biolabs (US), Nanofcm (UK), Izon Science (UK), and Malvern Panalytical (UK).

Research Coverage:

This research report categorizes the exosome research market by offering [kits & reagents (antibodies, isolation, purification, quantitation kits, reagents, and other kits & reagents), instruments, and services], indication [cancer indication (lung cancer, breast cancer, prostate cancer, colorectal cancer, other cancers), neurodegenerative diseases, cardiovascular diseases, infectious diseases, and other indications], by application [biomarkers, vaccine development, tissue regeneration, and other applications], by manufacturing services [stem cell-derived exosome manufacturing services, dendritic cell-derived exosome manufacturing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

services, and other manufacturing services] by end user [academic & research institutes, pharmaceutical & biotechnological companies, and hospitals & clinical laboratories] and by region [North America, Europe, Asia Pacific, Latin America, Middle East & Africa].

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the exosome research market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the Exosome Research market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall exosome research market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (increasing investment in pharmaceutical & life sciences research, rising cancer prevalence, and increasing interest in exosome-based procedures), restraints (technical complexity of exosome isolation, and regulatory uncertainty in exosome research), opportunities (rising investments in emerging countries for exosome research, growing interest in exosome-based therapeutics, and increasing demand for personalized medicines), and Challenges (lack of gold standard protocols for exosome development and production and limited understanding of cargo loading).
- Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the exosome research market.
- Market Development: Comprehensive information about lucrative markets; the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the exosome research market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the exosome research market.

Table of Contents:

1	INTRODUCTION	31
1.1	STUDY OBJECTIVES	31
1.2	MARKET DEFINITION	31
1.3	STUDY SCOPE	32
1.3.1	MARKET SEGMENTATION & REGIONAL SCOPE	32
1.3.2	INCLUSIONS & EXCLUSIONS	33
1.3.3	YEARS CONSIDERED	33
1.3.4	CURRENCY CONSIDERED	34
1.4	STAKEHOLDERS	34
1.5	SUMMARY OF CHANGES	34
2	RESEARCH METHODOLOGY	36
2.1	RESEARCH DATA	36
2.1.1	SECONDARY DATA	37
2.1.1.1	Objectives of secondary research	37
2.1.1.2	Key data from secondary sources	38
2.1.2	PRIMARY DATA	38

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.1.2.1	Breakdown of primaries	39
2.1.2.2	Key objective of primary research	39
2.2	MARKET ESTIMATION	40
2.2.1	GLOBAL MARKET ESTIMATION	41
2.2.1.1	Company revenue analysis (bottom-up approach)	41
2.2.1.2	Revenue share analysis of Thermo Fisher Scientific Inc.	42
2.2.1.3	MnM repository analysis	42
2.2.1.4	Primary interviews	43
2.2.2	INSIGHTS FROM PRIMARY EXPERTS	43
2.2.3	SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)	44
2.3	MARKET GROWTH RATE PROJECTIONS	45
2.4	DATA TRIANGULATION	47
2.5	STUDY ASSUMPTIONS	47
2.6	RESEARCH LIMITATIONS	48
2.7	RISK ANALYSIS	48
3	EXECUTIVE SUMMARY	49
4	PREMIUM INSIGHTS	53
4.1	EXOSOME RESEARCH MARKET OVERVIEW	53
4.2	NORTH AMERICA: EXOSOME RESEARCH MARKET, BY APPLICATION AND COUNTRY	54
4.3	EXOSOME RESEARCH MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	55
5	MARKET OVERVIEW	56
5.1	INTRODUCTION	56
5.2	MARKET DYNAMICS	56
5.2.1	DRIVERS	57
5.2.1.1	Increasing investment in pharmaceutical and life sciences R&D	57
5.2.1.2	Rising focus on development of cancer therapeutics and diagnostics	58
5.2.1.3	Growing interest in exosome-based procedures	59
5.2.2	RESTRAINTS	60
5.2.2.1	Technical complexity of exosome isolation and characterization	60
5.2.2.2	Regulatory complications and uncertainty in exosome research	60
5.2.3	OPPORTUNITIES	61
5.2.3.1	High investments in emerging economies	61
5.2.3.2	Growing interest in exosome-based therapeutics	61
5.2.3.3	Rising demand for personalized medicines	62
5.2.4	CHALLENGES	63
5.2.4.1	Lack of standard protocols for exosome manufacturing and development	63
5.2.4.2	Limited understanding of cargo loading capacity	63
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	64
5.4	PRICING ANALYSIS	64
5.4.1	INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY KEY PLAYER, 2024	65
5.4.2	INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY REGION, 2024	66
5.5	VALUE CHAIN ANALYSIS	68
5.6	SUPPLY CHAIN ANALYSIS	69
5.7	ECOSYSTEM ANALYSIS	70
5.7.1	ROLE IN ECOSYSTEM	71
5.8	TECHNOLOGY ANALYSIS	72

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.8.1	KEY TECHNOLOGIES	72
5.8.1.1	Ultracentrifugation	72
5.8.1.2	Nanoparticle tracking analysis (NTA)	72
5.8.2	COMPLIMENTARY TECHNOLOGIES	72
5.8.2.1	Microfluidics	72
5.8.2.2	Western blotting/ELISA	72
5.8.3	ADJACENT TECHNOLOGIES	73
5.8.3.1	Next-generation sequencing	73
5.8.3.2	Mass spectrometry	73
5.9	PATENT ANALYSIS	73
5.9.1	NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2024	73
5.9.2	LIST OF KEY PATENTS, 2023-2024	75
5.10	KEY CONFERENCES & EVENTS, 2025-2026	76
	?	
5.11	REGULATORY ANALYSIS	77
5.11.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	78
5.11.2	REGULATORY FRAMEWORK	80
5.11.2.1	North America	80
5.11.2.1.1	US	80
5.11.2.1.2	Canada	81
5.11.2.2	Europe	81
5.11.2.2.1	Germany	81
5.11.2.2.2	France	82
5.11.2.2.3	UK	82
5.11.2.3	Asia Pacific	82
5.11.2.3.1	China	82
5.11.2.3.2	Japan	83
5.11.2.3.3	India	83
5.11.2.4	Rest of the World	83
5.11.2.4.1	Brazil	83
5.11.2.4.2	Argentina	84
5.11.2.4.3	Saudi Arabia	84
5.12	PORTER'S FIVE FORCES ANALYSIS	84
5.12.1	THREAT OF NEW ENTRANTS	85
5.12.2	THREAT OF SUBSTITUTES	86
5.12.3	BARGAINING POWER OF SUPPLIERS	86
5.12.4	BARGAINING POWER OF BUYERS	86
5.12.5	INTENSITY OF COMPETITIVE RIVALRY	86
5.13	KEY STAKEHOLDERS & BUYING CRITERIA	87
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	87
5.13.2	KEY BUYING CRITERIA	88
5.14	INVESTMENT & FUNDING SCENARIO	90
5.15	TRADE DATA ANALYSIS	91
5.15.1	IMPORT DATA FOR HS CODE 3822, 2020-2024	91
5.15.2	EXPORT DATA FOR HS CODE 3822, 2020-2024	93
5.16	IMPACT OF AI/GEN AI ON EXOSOME RESEARCH MARKET	94

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.17 □ IMPACT OF 2025 US TARIFF ON EXOSOME RESEARCH MARKET □ 95
 - 5.17.1 □ INTRODUCTION □ 95
 - 5.17.2 □ KEY TARIFF RATES □ 96
 - 5.17.3 □ PRICE IMPACT ANALYSIS □ 97
 - 5.17.4 □ IMPACTS ON COUNTRY/REGION □ 98
 - 5.17.4.1 □ North America □ 98
 - 5.17.4.1.1 □ US □ 98
 - 5.17.4.2 □ Europe □ 99
 - 5.17.4.3 □ Asia Pacific □ 99
 - 5.17.5 □ IMPACT ON END-USE INDUSTRIES □ 99
 - 5.17.5.1 □ Academic & research institutes □ 99
 - 5.17.5.2 □ Pharmaceutical & biotechnology companies □ 100
 - 5.17.5.3 □ Hospitals & clinical laboratories □ 100
- 6 □ EXOSOME RESEARCH MARKET, BY OFFERING □ 101
 - 6.1 □ INTRODUCTION □ 102
 - 6.2 □ KITS & REAGENTS □ 102
 - 6.2.1 □ ANTIBODIES □ 105
 - 6.2.1.1 □ High demand for exosome-based markers for disease detection to propel market growth □ 105
 - 6.2.2 □ ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS □ 108
 - 6.2.2.1 □ Availability of rapid and easy-to-use kits & reagents to ensure sustained demand □ 108
 - 6.2.3 □ OTHER KITS & REAGENTS □ 110
 - 6.3 □ INSTRUMENTS □ 113
 - 6.3.1 □ DEMAND FOR SCALABLE EXOSOME DEVELOPMENT THROUGH HIGH-THROUGHPUT SYSTEMS TO DRIVE GROWTH □ 113
 - 6.4 □ SERVICES □ 116
 - 6.4.1 □ LACK OF IN-HOUSE RESOURCES TO SUPPORT MARKET GROWTH □ 116
- 7 □ EXOSOME RESEARCH MARKET, BY INDICATION □ 119
 - 7.1 □ INTRODUCTION □ 120
 - 7.2 □ CANCER □ 120
 - 7.2.1 □ LUNG CANCER □ 123
 - 7.2.1.1 □ Increasing demand for advanced diagnostics for lung cancer to propel market growth □ 123
 - 7.2.2 □ BREAST CANCER □ 126
 - 7.2.2.1 □ Increased awareness and focus on better non-invasive diagnosis to aid market growth □ 126
 - 7.2.3 □ PROSTATE CANCER □ 128
 - 7.2.3.1 □ Effectiveness of liquid biopsy in detecting prostate cancer before surgery to support market growth □ 128
 - 7.2.4 □ COLORECTAL CANCER □ 131
 - 7.2.4.1 □ Rising focus on exosome-based research on tumor initiation, progression, chemoresistance, and metastasis to drive market □ 131
 - 7.2.5 □ OTHER CANCERS □ 133
 - 7.3 □ NEURODEGENERATIVE DISEASES □ 136
 - 7.3.1 □ INCREASED APPLICATION OF SALIVARY EXOSOMAL CARGO CONTENT IN DISEASE TREATMENT TO PROPEL MARKET GROWTH □ 136
 - 7.4 □ CARDIOVASCULAR DISEASES □ 139
 - 7.4.1 □ GREATER RESEARCH FOCUS ON EXTRACELLULAR VESICLES TO AUGMENT MARKET GROWTH □ 139
 - 7.5 □ INFECTIOUS DISEASES □ 141
 - 7.5.1 □ POTENTIAL FOR EXOSOMES IN DEVELOPING NOVEL INFECTIOUS DISEASE TREATMENTS TO AID ADOPTION □ 141
 - 7.6 □ OTHER INDICATIONS □ 144

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8	EXOSOME RESEARCH MARKET, BY APPLICATION	147
8.1	INTRODUCTION	148
8.2	BIOMARKERS	148
8.2.1	ABILITY TO MODULATE CELL SIGNALING AND REDUCE NEUROINFLAMMATION TO DRIVE ADOPTION	148
8.3	VACCINE DEVELOPMENT	151
8.3.1	NEED FOR COMBATING INFECTIOUS DISEASES TO SPUR ADOPTION OF EXOSOME-BASED VACCINES	151
8.4	TISSUE REGENERATION	154
8.4.1	MINIMAL SIDE EFFECTS AND HIGH EFFICACY OF EXOSOMES IN TISSUE REGENERATION TO SUPPORT ADOPTION	154
8.5	OTHER APPLICATIONS	157
9	EXOSOME RESEARCH MARKET, BY MANUFACTURING SERVICE	160
9.1	INTRODUCTION	161
9.2	STEM CELL-DERIVED EXOSOME MANUFACTURING	161
9.2.1	INCREASE IN DEMAND FOR MESENCHYMAL STEM CELLS-BASED EXOSOMES IN THERAPEUTICS TO AUGMENT MARKET GROWTH	161
9.3	DENDRITIC CELL-DERIVED EXOSOME MANUFACTURING	162
9.3.1	SIGNIFICANT DEVELOPMENTS IN DENDRITIC CELL-BASED EXOSOME IMMUNOTHERAPY TO DRIVE MARKET	162
9.4	OTHER MANUFACTURING SERVICES	162
10	EXOSOME RESEARCH MARKET, BY END USER	163
10.1	INTRODUCTION	164
10.2	ACADEMIC & RESEARCH INSTITUTES	164
10.2.1	INCREASING NUMBER OF CANCER AND STEM CELL RESEARCH PROJECTS GLOBALLY TO AUGMENT MARKET GROWTH	164
10.3	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	167
10.3.1	HIGH INVESTMENTS AND RAPID INNOVATIONS IN EXOSOME-BASED DIAGNOSTICS TO AID MARKET GROWTH	167
10.4	HOSPITALS & CLINICAL TESTING LABORATORIES	170
10.4.1	RISING ADOPTION OF EXOSOME-BASED ONCOLOGY RESEARCH SOLUTIONS TO PROPEL MARKET GROWTH	170
	?	
11	EXOSOME RESEARCH MARKET, BY REGION	173
11.1	INTRODUCTION	174
11.2	NORTH AMERICA	175
11.2.1	MACROECONOMIC ANALYSIS FOR NORTH AMERICA	176
11.2.2	US	180
11.2.2.1	US to dominate North American exosome research market during study period	180
11.2.3	CANADA	183
11.2.3.1	Increasing funding for genome-based medical treatments to support market growth	183
11.3	EUROPE	186
11.3.1	MACROECONOMIC ANALYSIS FOR EUROPE	186
11.3.2	GERMANY	190
11.3.2.1	Advanced biotechnology sector and developed research facilities to favor market growth	190
11.3.3	UK	193
11.3.3.1	Favorable R&D initiatives and advanced life science industry to drive market	193
11.3.4	FRANCE	196
11.3.4.1	Increasing collaborations between biotechnology firms and research institutes to propel market growth	196
11.3.5	ITALY	199
11.3.5.1	Favorable government policies to propel growth of exosome research	199
11.3.6	SPAIN	201
11.3.6.1	Increased focus on pharmaceutical R&D to aid market growth	201
11.3.7	REST OF EUROPE	204

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.4	ASIA PACIFIC	206
11.4.1	MACROECONOMIC ANALYSIS FOR ASIA PACIFIC	207
11.4.2	CHINA	210
11.4.2.1	Favorable government initiatives for development of biotechnology industry to drive market	210
11.4.3	JAPAN	213
11.4.3.1	High prevalence of cancer and increased healthcare expenditure to aid market growth	213
11.4.4	INDIA	216
11.4.4.1	Increasing number of institutional alliances and growing focus on clinical innovation to support market growth	216
11.4.5	AUSTRALIA	218
11.4.5.1	Substantial government funding and innovative applications in regenerative medicines to augment market growth	218
11.4.6	SOUTH KOREA	221
11.4.6.1	Favorable government initiatives and routine clinical trials to support market growth	221
11.4.7	REST OF ASIA PACIFIC	224
	?	
11.5	LATIN AMERICA	227
11.5.1	MACROECONOMIC ANALYSIS FOR LATIN AMERICA	227
11.5.2	BRAZIL	231
11.5.2.1	Increased government investments in pharmaceutical R&D to drive market	231
11.5.3	MEXICO	234
11.5.3.1	Advancements in regenerative medicines and exosome-based therapies to support market growth	234
11.5.4	REST OF LATIN AMERICA	236
11.6	MIDDLE EAST & AFRICA	239
11.6.1	MACROECONOMIC ANALYSIS FOR MIDDLE EAST & AFRICA	239
11.6.2	GCC COUNTRIES	243
11.6.2.1	Strong focus on local pharmaceutical R&D to fuel market growth	243
11.6.3	REST OF MIDDLE EAST & AFRICA	246
12	COMPETITIVE LANDSCAPE	250
12.1	INTRODUCTION	250
12.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	250
12.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EXOSOME RESEARCH MARKET	250
12.3	REVENUE ANALYSIS, 2020-2024	252
12.4	MARKET SHARE ANALYSIS, 2024	253
12.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	255
12.5.1	STARS	255
12.5.2	EMERGING LEADERS	255
12.5.3	PERVASIVE PLAYERS	256
12.5.4	PARTICIPANTS	256
12.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	257
12.5.5.1	Company footprint	257
12.5.5.2	Region footprint	258
12.5.5.3	Offering footprint	259
12.5.5.4	Indication footprint	260
12.5.5.5	Application footprint	261
12.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	261
12.6.1	PROGRESSIVE COMPANIES	261
12.6.2	RESPONSIVE COMPANIES	262
12.6.3	DYNAMIC COMPANIES	262

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.6.4	STARTING BLOCKS	262
12.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	263
12.6.5.1	Detailed list of key startups/SMEs	263
12.6.5.2	Competitive benchmarking of key startups/SME players, by offering and region	264
	?	
12.7	COMPANY VALUATION & FINANCIAL METRICS	265
12.7.1	FINANCIAL METRICS	265
12.7.2	COMPANY VALUATION	265
12.8	BRAND/PRODUCT COMPARISON	266
12.9	COMPETITIVE SCENARIO	267
12.9.1	PRODUCT LAUNCHES & APPROVALS	267
12.9.2	DEALS	268
12.9.3	EXPANSIONS	269
13	COMPANY PROFILES	270
13.1	KEY PLAYERS	270
13.1.1	THERMO FISHER SCIENTIFIC INC.	270
13.1.1.1	Business overview	270
13.1.1.2	Products/Services/Solutions offered	271
13.1.1.3	Recent developments	273
13.1.1.3.1	Deals	273
13.1.1.4	MnM view	273
13.1.1.4.1	Key strengths	273
13.1.1.4.2	Strategic choices	273
13.1.1.4.3	Weaknesses & competitive threats	273
13.1.2	QIAGEN	274
13.1.2.1	Business overview	274
13.1.2.2	Products/Services/Solutions offered	275
13.1.2.3	Recent developments	276
13.1.2.3.1	Product launches	276
13.1.2.4	MnM view	276
13.1.2.4.1	Key strengths	276
13.1.2.4.2	Strategic choices	276
13.1.2.4.3	Weaknesses & competitive threats	276
13.1.3	LONZA	277
13.1.3.1	Business overview	277
13.1.3.2	Products/Services/Solutions offered	278
13.1.3.3	Recent developments	279
13.1.3.3.1	Deals	279
13.1.3.3.2	Expansions	279
13.1.3.4	MnM view	279
13.1.3.4.1	Key strengths	279
13.1.3.4.2	Strategic choices	280
13.1.3.4.3	Weaknesses & competitive threats	280
13.1.4	DANAHER	281
13.1.4.1	Business overview	281
13.1.4.2	Products/Services/Solutions offered	283
13.1.4.3	Recent developments	283

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1.4.3.1 Product launches 283
- 13.1.4.3.2 Deals 284
- 13.1.4.4 MnM view 284
- 13.1.4.4.1 Key strengths 284
- 13.1.4.4.2 Strategic choices 284
- 13.1.4.4.3 Weaknesses & competitive threats 284
- 13.1.5 BIO-TECHNE 285
- 13.1.5.1 Business overview 285
- 13.1.5.2 Products/Services/Solutions offered 286
- 13.1.5.3 Recent developments 287
- 13.1.5.3.1 Product launches 287
- 13.1.5.4 MnM view 287
- 13.1.5.4.1 Key strengths 287
- 13.1.5.4.2 Strategic choices 287
- 13.1.5.4.3 Weaknesses & competitive threats 287
- 13.1.6 SYSTEM BIOSCIENCES, LLC 288
- 13.1.6.1 Business overview 288
- 13.1.6.2 Products/Services/Solutions offered 288
- 13.1.7 AMSBIO 290
- 13.1.7.1 Business overview 290
- 13.1.7.2 Products/Services/Solutions offered 291
- 13.1.8 ROOSTERBIO, INC. 292
- 13.1.8.1 Business overview 292
- 13.1.8.2 Products/Services/Solutions offered 292
- 13.1.8.3 Recent developments 293
- 13.1.8.3.1 Deals 293
- 13.1.9 MILTENYI BIOTECH 294
- 13.1.9.1 Business overview 294
- 13.1.9.2 Products/Services/Solutions offered 294
- 13.1.9.3 Recent developments 295
- 13.1.9.3.1 Product launches 295
- 13.1.10 NORGEN BIOTEK CORP. 296
- 13.1.10.1 Business overview 296
- 13.1.10.2 Products/Services/Solutions offered 296
- 13.1.11 AETHLON MEDICAL, INC. 298
- 13.1.11.1 Business overview 298
- 13.1.11.2 Products/Services/Solutions offered 299
- 13.1.11.3 Recent developments 299
- 13.1.11.3.1 Product approvals 299
- ?
- 13.1.12 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC. 300
- 13.1.12.1 Business overview 300
- 13.1.12.2 Products/Services/Solutions offered 300
- 13.1.13 SPECTRIS 301
- 13.1.13.1 Business overview 301
- 13.1.13.2 Products/Services/Solutions offered 302
- 13.1.13.3 Recent developments 303

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.13.3.1	Product launches	303
13.1.13.3.2	Deals	303
13.1.14	NANOFCM, INC.	304
13.1.14.1	Business overview	304
13.1.14.2	Products/Services/Solutions offered	304
13.1.15	IZON SCIENCE LIMITED	305
13.1.15.1	Business overview	305
13.1.15.2	Products/Services/Solutions offered	305
13.1.16	CAPRICOR THERAPEUTICS, INC.	306
13.1.16.1	Business overview	306
13.1.16.2	Products/Services/Solutions offered	307
13.2	OTHER PLAYERS	308
13.2.1	ANJARIUM BIOSCIENCES AG	308
13.2.2	CILOA	308
13.2.3	INNOVAPREP	309
13.2.4	ILIAS BIOLOGICS INC.	309
13.2.5	UNCHAINED LABS	310
13.2.6	RION INC.	310
13.2.7	CELL GUIDANCE SYSTEM LLC	311
13.2.8	INVIQ	312
13.2.9	NX PHARMAGEN	312
13.2.10	EXOPHARM	313
13.2.11	EVERZOM	314
13.2.12	NANOSOMIX	314
13.2.13	CREATIVE BIOLABS	315
14	APPENDIX	317
14.1	DISCUSSION GUIDE	317
14.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	321
14.3	CUSTOMIZATION OPTIONS	323
14.4	RELATED REPORTS	323
14.5	AUTHOR DETAILS	324

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030

Market Report | 2025-06-10 | 325 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature